BCHE and Alzheimer disease: Currently, commercially available therapeutics for the treatment of AD have been developed to inhibit several pathologic targets, including cholinesterase inhibitors (e.g., donepezil, galantamine, and rivastigmine), N-methyl-D-aspartate (NMDA) receptor antagonists (e.g., memantine), and a monoclonal antibody that directly disrupts Aβ (aducanumab), as shown in Table 1.